Keryx (KERX) Launches Renal Drug Auryxia in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:35PM CST
Keryx Biopharmaceuticals, Inc. (KERX) announced it has begun to ship Auryxia (ferric citrate) tablets to wholesalers in the U.S.
AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), SCMP: 13.75 (+0.44), KERX: 14.00 (+0.20)
Gilead/Ono Pharmaceutical Ink Deal for Blood Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:12PM CST
Gilead Sciences, Inc. and Ono Pharmaceutical Co., Ltd. announced that they have entered into an agreement for ONO-4059.
VRX: 140.33 (-0.22), GILD: 91.29 (+1.84), SCMP: 13.75 (+0.44)
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 3:45PM CST
Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's anti-bacterial program.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), EBS: 27.64 (+1.28), SCMP: 13.75 (+0.44)
UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:20PM CST
UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for the acquisition of UCB's Kremers Urban.
LCI: 42.29 (+1.79), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)
Uptrend Call Working As Sucampo Pharmaceuticals Stock Rises 92.8% (SCMP)
Comtex SmarTrend(R) - Thu Dec 18, 9:35AM CST
SmarTrend identified an Uptrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on August 13th, 2014 at $6.98. In approximately 4 months, Sucampo Pharmaceuticals has returned 92.84% as of today's recent price of $13.46.
SCMP: 13.75 (+0.44)
Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:00PM CST
In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), CYCC: 0.69 (+0.01), SCMP: 13.75 (+0.44)
Salix Gains on Destocking Initiatives, Gives 2-Year Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 1:12PM CST
Salix (SLXP) expects to resolve its inventory situation a year ahead of schedule and now expects a FDA response on Xifaxan 550 by May 27, 2015.
LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44), SLXP: 114.92 (-1.18), BIOD: 1.36 (-0.04)
Alexion Announces New Share Repurchase Program of $500M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:55PM CST
Alexion Pharmaceuticals, Inc. (ALXN) announced that a new share repurchase program of up to $500 million have been authorized by its board of directors.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44), ALXN: 181.96 (+3.09)
Sophiris Plunges on Disappointing Data on its BPH Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:30PM CST
Sophiris Bio Inc.'s (SPHS) shares plummeted 81.5% after the company announced disappointing data from an interim efficacy analysis of its ongoing phase III study on PRX302.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), SPHS: 0.46 (+0.02), SCMP: 13.75 (+0.44)
Calithera Biosciences Slumps: CALA Tanks 10.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:50AM CST
Calithera Biosciences (CALA) fell by over 10% in the last trading session amid huge volumes, reversing its recent uptrend, as the stock is now up nearly 185% in the past one month.
LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44), CALA: 22.33 (+1.16), IG: 9.11 (-0.01)
Sucampo names John H. Johnson to board
M2 - Tue Dec 16, 6:04AM CST
Biopharmaceutical company Sucampo Pharmaceuticals (NasdaqGM:SCMP)revealed on Monday the election of John H. Johnson to its board of directors.
PTLA: 28.35 (+0.21), SCMP: 13.75 (+0.44)
One Stock Chart Trick You Should All Know - Investment Ideas
David Bartosiak - ZACKS - Tue Dec 16, 12:00AM CST
One Stock Chart Trick You Should All Know - Investment Ideas
HSKA: 18.13 (+0.24), ANIP: 55.24 (+1.79), SCMP: 13.75 (+0.44)
ChemoCentryx Up on Positive Diabetic Nephropathy Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 5:45PM CST
ChemoCentryx, Inc., announced positive top-line 52-week data from its phase II study on its candidate CCX140 for diabetic nephropathy.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44), CCXI: 6.64 (-0.04)
Astellas-Medivation Reveal Data on Xtandi for Breast Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 2:00PM CST
Astellas Pharma Inc. (ALPMY) and Medivation announced the presentation of stage I and preliminary stage II data from a phase II study on Xtandi triple negative breast cancer.
MDVN: 99.23 (+1.23), LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44)
Cerulean Pharma (CERU) Worth Watching: Stock Rises 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:39AM CST
Cerulean Pharma Inc. (CERU) was a big mover last session, as its shares rose over 16% on the day.
LCI: 42.29 (+1.79), CERU: 6.45 (unch), SCMP: 13.75 (+0.44), IG: 9.11 (-0.01)
Flexion Therapeutics (FLXN) Worth Watching: Stock Up 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:25AM CST
Flexion Therapeutics (FLXN) was a big mover last session, with shares rising over 9% on the day.
LCI: 42.29 (+1.79), FLXN: 20.56 (+0.02), SCMP: 13.75 (+0.44), IG: 9.11 (-0.01)
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 24.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 7:51AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as its shares rose almost 25% on the day.
LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44), CCXI: 6.64 (-0.04), IG: 9.11 (-0.01)
Sucampo Appoints John H. Johnson to Board of Directors
GlobeNewswire - Mon Dec 15, 5:45AM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the appointment of John H. Johnson, founder, Plum Brook Advisors, to its board of directors (Board).
SCMP: 13.75 (+0.44)
What Falling Estimates & Price Mean for Immune Design Corp. (IMDZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 7:39AM CST
One stock that you may want to consider dropping is Immune Design Corp. (IMDZ), which has witnessed a significant price decline in the past four weeks
LCI: 42.29 (+1.79), IMDZ: 34.96 (+0.78), SCMP: 13.75 (+0.44), IG: 9.11 (-0.01)